Gilead Sciences announced a partnership with PAHO to expand access to its twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. This agreement establishes a regional pathway for adoption and complements existing generic access, potentially increasing Gilead's market reach in these regions.
Gilead Sciences has entered into an agreement with the Pan American Health Organization (PAHO) to facilitate broader access to its long-acting HIV prevention drug, lenacapavir, across Latin America and the Caribbean. This partnership is significant as it creates a new regional pathway for the drug's adoption in 14 countries not covered by existing voluntary licensing agreements, complementing generic access. For Gilead, this represents an opportunity to expand its market share and address a growing public health need in a region where new HIV infections have increased. While not a blockbuster announcement, it signals a strategic move to secure future revenue streams and solidify its position in the HIV prevention market, with long-term positive implications for the company's growth trajectory in emerging markets.